| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| EPM2A | GSK3B | ENSP00000356489 | ENSP00000324806 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | glycogen synthase kinase 3 beta; Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glyc [...] | 0.930 |
| EPM2A | GYS1 | ENSP00000356489 | ENSP00000317904 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | glycogen synthase 1 (muscle); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | 0.988 |
| EPM2A | GYS2 | ENSP00000356489 | ENSP00000261195 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | glycogen synthase 2 (liver); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | 0.964 |
| EPM2A | NFU1 | ENSP00000356489 | ENSP00000387219 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae); Iron-sulfur cluster scaffold protein which can assemble [4Fe-2S] clusters and deliver them to target proteins | 0.947 |
| EPM2A | NHLRC1 | ENSP00000356489 | ENSP00000345464 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | NHL repeat containing 1; E3 ubiquitin-protein ligase which in complex with EPM2A/laforin and HSP70 suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Ubiquitinates PPP1R3C/PTG in a laforin-dependent manner, and targets it for proteasome-dependent degradation and this degradation decreases glycogen accumulation. Polyubiquitinates EPM2A/laforin and ubiquitinates AGL and targets them for proteasome-dependent degradation | 0.999 |
| EPM2A | PPP1R3C | ENSP00000356489 | ENSP00000238994 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | protein phosphatase 1, regulatory subunit 3C; Acts as a glycogen-targeting subunit for PP1 and regulates its activity. Activates glycogen synthase, reduces glycogen phosphorylase activity and limits glycogen breakdown. Dramatically increases basal and insulin-stimulated glycogen synthesis upon overexpression in a variety of cell types | 0.994 |
| EPM2A | RPS27A | ENSP00000356489 | ENSP00000272317 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | ribosomal protein S27a | 0.905 |
| EPM2A | UBA52 | ENSP00000356489 | ENSP00000388107 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | ubiquitin A-52 residue ribosomal protein fusion product 1 | 0.905 |
| EPM2A | UBB | ENSP00000356489 | ENSP00000304697 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | ubiquitin B | 0.906 |
| EPM2A | UBC | ENSP00000356489 | ENSP00000344818 | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | ubiquitin C | 0.981 |
| GSK3B | EPM2A | ENSP00000324806 | ENSP00000356489 | glycogen synthase kinase 3 beta; Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glyc [...] | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | 0.930 |
| GSK3B | GYS1 | ENSP00000324806 | ENSP00000317904 | glycogen synthase kinase 3 beta; Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glyc [...] | glycogen synthase 1 (muscle); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | 0.999 |
| GSK3B | GYS2 | ENSP00000324806 | ENSP00000261195 | glycogen synthase kinase 3 beta; Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glyc [...] | glycogen synthase 2 (liver); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | 0.947 |
| GSK3B | NHLRC1 | ENSP00000324806 | ENSP00000345464 | glycogen synthase kinase 3 beta; Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glyc [...] | NHL repeat containing 1; E3 ubiquitin-protein ligase which in complex with EPM2A/laforin and HSP70 suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Ubiquitinates PPP1R3C/PTG in a laforin-dependent manner, and targets it for proteasome-dependent degradation and this degradation decreases glycogen accumulation. Polyubiquitinates EPM2A/laforin and ubiquitinates AGL and targets them for proteasome-dependent degradation | 0.407 |
| GSK3B | UBC | ENSP00000324806 | ENSP00000344818 | glycogen synthase kinase 3 beta; Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glyc [...] | ubiquitin C | 0.970 |
| GYS1 | EPM2A | ENSP00000317904 | ENSP00000356489 | glycogen synthase 1 (muscle); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) | 0.988 |
| GYS1 | GSK3B | ENSP00000317904 | ENSP00000324806 | glycogen synthase 1 (muscle); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | glycogen synthase kinase 3 beta; Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glyc [...] | 0.999 |
| GYS1 | GYS2 | ENSP00000317904 | ENSP00000261195 | glycogen synthase 1 (muscle); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | glycogen synthase 2 (liver); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | 0.902 |
| GYS1 | NFU1 | ENSP00000317904 | ENSP00000387219 | glycogen synthase 1 (muscle); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae); Iron-sulfur cluster scaffold protein which can assemble [4Fe-2S] clusters and deliver them to target proteins | 0.529 |
| GYS1 | NHLRC1 | ENSP00000317904 | ENSP00000345464 | glycogen synthase 1 (muscle); Transfers the glycosyl residue from UDP-Glc to the non- reducing end of alpha-1,4-glucan | NHL repeat containing 1; E3 ubiquitin-protein ligase which in complex with EPM2A/laforin and HSP70 suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Ubiquitinates PPP1R3C/PTG in a laforin-dependent manner, and targets it for proteasome-dependent degradation and this degradation decreases glycogen accumulation. Polyubiquitinates EPM2A/laforin and ubiquitinates AGL and targets them for proteasome-dependent degradation | 0.985 |
Share
